CCM
RLAY icon

CAAS Capital Management’s Relay Therapeutics RLAY Stock Holding History

CAAS Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-34,000
Closed -$508K – 877
2022
Q4 		$508K Sell
34,000
-75,598
-69% -$1.45M 0.03% 429
2022
Q3 		$2.45M Buy
+109,598
New +$2.4M 0.12% 249
2021
Q2 		– Sell
-65,790
Closed -$2.27M – 1241
2021
Q1 		$2.27M Buy
+65,790
New +$2.86M 0.02% 566

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CAAS Capital Management's RLAY Position: Q1 2023 in Review

CAAS Capital Management sold out of Relay Therapeutics (RLAY) in Q1 2023, closing a stake of 34,000 shares — an estimated $508K sold.

CAAS Capital Management first reported a position in RLAY in Q1 2021 and held it in 3 quarters. The position peaked at $2.45M in Q3 2022. 157 funds tracked by Wall St. Rank hold RLAY as of Q1 2023.

  • CAAS Capital Management reported no remaining Relay Therapeutics position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 34,000 Relay Therapeutics shares in Q1 2023, an estimated $508K.
  • CAAS Capital Management first reported a position in Relay Therapeutics in Q1 2021 and held it in 3 quarters.
  • CAAS Capital Management's Relay Therapeutics position peaked at $2.45M in Q3 2022.
  • 157 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.